Genetix Biotherapeutics

Genetix Biotherapeutics is dedicated to transforming lives through curative therapies. Formerly bluebird bio, Genetix Biotherapeutics Inc. Is a privately held, commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases. The company has three FDA-approved genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These first-in-class, one-time administered therapies treat the underlying cause of disease and can offer significant and lasting benefits to patients and their families. Genetix is now better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies. As we enter this new era, Genetix Biotherapeutics is building an ecosystem to expand awareness and access for thousands of untreated patients. Rooted in decades of scientific innovation, we are sharpening our focus on commercial execution, scaling patient access, and enhancing the treatment experience for patients, families, and providers.